A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Luca Gentile, Teresa Coelho, Angela Dispenzieri...
https://pubmed.ncbi.nlm.nih.gov/37946256/Actively Recruiting
Led by Hospital 9 de Julio de Las Breñas · Updated on 2026-04-02
57
Participants Needed
2
Research Sites
8 weeks
Total Duration
Researchers are studying hereditary transthyretin amyloidosis ATTRv with the Val50Met genetic variant in a population where this condition is not common. The goal is to describe different physical signs and symptoms, including early signs before symptoms appear, heart-related, nerve-related, and mixed manifestations. This research aims to help identify early disease signs in people who do not show symptoms initially, improving early detection and treatment approaches. Participants carry the Val50Met variant and will undergo a series of clinical exams and tests. These include a full physical exam, neurological assessments such as motor strength and sensory testing, heart monitoring with ECG and echocardiography, and various questionnaires assessing quality of life and nerve function. Additional tests include electromyograms, specific heart imaging scans, and laboratory tests analyzing blood and urine samples for various biomarkers. During the study, participants will be evaluated over a period of two years to gather detailed information about their health status. Researchers will review preclinical and clinical variables related to heart and nerve function and quality of life measures. The study includes regular clinical exams, diagnostic imaging, questionnaire assessments, and laboratory testing to monitor disease manifestations and potential early onset signs in carriers of the genetic variant.
CONDITIONS
Phenotypic Manifestations of Hereditary ATTR Amyloidosis
M
Mauricio MT TOMEI, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital 9 de Julio de Las Breñas
Lead Sponsor
Instituto de Cardiología de Corrientes
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Throughout the study period of 2 years
Participants undergo various clinical examinations and diagnostic tests to gather comprehensive data on their condition.
Initial and periodic visits over 2 years for assessments including physical exams, neurological tests, ECG, Holter monitoring, echocardiography, EMG, scintigraphy, laboratory tests, and questionnaires
Duration - 2 years
Participants are observed over time to describe phenotypic variables and explore early disease onset criteria.
Regular follow-up visits during the 2-year observation period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Luca Gentile, Teresa Coelho, Angela Dispenzieri...
https://pubmed.ncbi.nlm.nih.gov/37946256/Maria S Saez, Maria A Aguirre, Diego Pérez de Arenaza...
https://pubmed.ncbi.nlm.nih.gov/34668655/Isabel Conceição, Thibaud Damy, Manuel Romero...
https://pubmed.ncbi.nlm.nih.gov/30793974/Mathew S Maurer, Sabahat Bokhari, Thibaud Damy...
https://pubmed.ncbi.nlm.nih.gov/31480867/Hospital 9 de Julio de Las Breñas
Lead Sponsor
Instituto de Cardiología de Corrientes
Collaborating Sponsor